Press Releases

Arch Therapeutics Withdraws 510(k) with Plans to Resubmit After Further Discussions with FDA
Arch Therapeutics to Provide Corporate Update at the 10th Annual LD Micro Main Event In Los Angeles December 5-7, 2017
Arch Therapeutics to Provide Corporate Updates at Upcoming Industry and Investment Conferences
Arch Therapeutics Reports Favorable Results in Repeat Dose Testing of AC5™ for Subchronic Systemic Toxicity
Arch Therapeutics to Provide Corporate Update at the 19th Annual Rodman & Renshaw Global Investment Conference In New York City September 10-12, 2017
Arch Therapeutics Announces 510(k) Submission to the U.S. FDA for AC5(TM) Topical Gel
Arch Therapeutics Presents Corporate Update at the LD Micro Invitational on Tuesday, June 6, 2017
Arch Therapeutics to Provide Corporate Update at the LD Micro Invitational on Tuesday, June 6, 2017
Arch Therapeutics to Provide Corporate Update at the 29th Annual Roth Conference on Monday, March 13, 2017
Arch Therapeutics to Provide Corporate Update at the Maxim Group - Haitong Securities Healthcare Investor and Partnering Conference
RSS
Show All